HOME >> BIOLOGY >> NEWS
From clinical cancer research: rethinking therapeutic cancer vaccine trials

Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patients immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way"

In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent chemotherapy or hormone treatment. The specific results or endpoints of these clinical trials, however, were not the long term survival of patients, but rather the degree to which the vaccine caused tumors to shrink. According to the researchers, since they didnt achieve their primary endpoints, these vaccines may be abandoned as dead-ends, despite their real therapeutic value in terms of prolonging patient survival.

Clinical data are providing evidence that patients are living longer following vaccination, de-spite the fact that trials do not show the vaccines can induce the immune system into shrinking tumors, said Jeffrey Schlom, Ph.D., chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. The data suggests that the scientific community and regulatory committees ought to rethink the design of clinical vaccine trials and our current approach to measuring the effectiveness of a cancer vaccine.

According to the researchers, it may be more helpful to think of the effectiveness of a vaccine in terms of the response of the patient, rather than the response of the tumor. While the Response Criteria in Solid Tumors (RECIST) experimental standards works well in evaluating therapies that are toxic to tumors, such as radiation or chemotherapy, they are less capable of me
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
3-Jul-2007


Page: 1 2

Related biology news :

1. Preclinical study links gene to brain aneurysm formation
2. Gene variant is associated with brain anatomy, clinical course of ADHD
3. New joint replacement material developed at MGH put to first clinical use
4. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
5. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
6. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
7. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
8. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
9. BDSI announces positive phase III clinical trial results
10. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
11. NIH announces phase III clinical trial of creatine for Parkinsons disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2018)... Calif. (PRWEB) , ... August 21, 2018 , ... ... engineer the genomes of diverse cell types and species for the robust functional ... research tool for the development of T-cell based immunotherapies, the study of the ...
(Date:8/21/2018)... ... 2018 , ... When designing a fluidic system for life ... what is designed can be manufactured reliably and cost effectively while meeting application ... design with specific focus on layered manifold technology. , Layered manifold technology allows ...
(Date:8/17/2018)... LIEGE, Belgium (PRWEB) , ... ... ... announced the acquisition of NXT-Dx, an established epigenetics service provider based in ... a number of targeted DNA methylation assays using pyrosequencing or Next-Generation Sequencing ...
Breaking Biology News(10 mins):
(Date:9/15/2018)... ... ... Nationally recognized public accounting and consulting firm Cherry Bekaert LLP (“the Firm”) ... on her appointment to Launch Tennessee’s Board of Directors. , Patrick has ... Firm’s Nashville practice in December 2017 . In this role, she oversees the execution ...
(Date:9/12/2018)... ... 12, 2018 , ... NDA Partners Chairman Carl Peck, MD, ... of Regulatory Affairs and Quality Systems at WellDoc, Inc., has joined the firm ... Quality Systems at WellDoc, Inc., she conducted quality control and supplier audits, led ...
(Date:9/7/2018)... ... September 06, 2018 , ... Akadeum Life Sciences today announced it has ... an executive and leader of numerous biotech companies. , He most recently served ... acquired by Thompson Street Capital in St. Louis, MO. Prior to ISTO, he ...
(Date:8/29/2018)... ... ... Cognition Corporation ®, a software company specializing in medical device compliance ... , Ryan Ward, Director of Engineering at Zimmer Biomet, has been announced as a ... with Zimmer Biomet for almost 15 years, Mr. Ward will focus his talk about ...
Breaking Biology Technology:
Cached News: